Observational studyInternational journal of clinical oncology2026
Real-world experience of circulating tumor DNA testing in resectable colorectal cancer: a Japanese single-institution observational study.
Observational study in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssessment of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) is a powerful prognostic tool for detecting postoperative recurrence in colorectal cancer (CRC). However, ctDNA-based MRD testing has been available only within clinical trials in Japan, and its clinical utility in patients ineligible for trials due to age or comorbidities remains unclear. We conducted a prospective observational study to describe the real-world implementation and clinical findings of postoperative ctDNA testing in CRC.
methodsCRC patients who underwent tumor-agnostic ctDNA MRD testing after curative-intent resection were prospectively enrolled. When ctDNA was detected, early imaging was performed to assess recurrence. Clinical outcomes were analyzed according to ctDNA status.
results56 CRC patients who underwent ctDNA testing 4-8 weeks after surgery between June 2023 and June 2025 were analyzed. 18 (32.1%) were ctDNA-positive and 38 (67.9%) were ctDNA-negative. Radiological recurrence occurred in 10 of 16 evaluable ctDNA-positive patients (62.5%), including liver metastases in 4 and no lung metastases. In contrast, recurrence was observed in 5 of 37 ctDNA-negative patients (13.5%), including lung metastases in 3 and no liver metastases. Three ctDNA-positive patients (18.8%) achieved ctDNA clearance after adjuvant chemotherapy and remained recurrence-free, whereas persistent-ctDNA positivity predicted disease progression. In the ctDNA-negative cohort, 84.5% remained disease-free regardless of adjuvant therapy.
conclusionsThis interim report demonstrates the feasibility of implementing postoperative ctDNA testing in real-world clinical practice. While exploratory and descriptive in nature, the findings suggest that ctDNA status may reflect recurrence risk and provide useful information for postoperative management in resectable CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.